AKRO

29.34

3.31% 0.94

Dopo l'orario di chiusura: 29.34

Akero Therapeutics Inc (AKRO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AKRO Giù? Forum Previsione

Precedente Chiudi:

$28.40

Aprire:

$28.09

Volume 24 ore:

1.48M

Relative Volume:

2.52

Capitalizzazione di mercato:

$2.05B

Reddito:

Utile/perdita netta:

$-237.22M

Rapporto P/E:

-11.46

EPS:

-2.56

Flusso di cassa netto:

$-212.64M

1 W Prestazione:

+1.56%

1M Prestazione:

-4.23%

6M Prestazione:

+34.71%

1 anno Prestazione:

+36.09%

Intervallo 1D:

$28.09

$29.77

Intervallo di 1 settimana:

$27.35

$31.41

Portata 52W:

$15.32

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Nome

Akero Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

650-487-6488

Indirizzo

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

@akerotx

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

AKRO's Discussions on Twitter

Confronta AKRO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AKRO Akero Therapeutics Inc	29.34	2.05B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-18	Iniziato	Citigroup	Buy
2024-04-22	Ripresa	BofA Securities	Neutral
2023-09-19	Iniziato	Cantor Fitzgerald	Overweight
2023-08-28	Iniziato	UBS	Buy
2023-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-09-14	Aggiornamento	Evercore ISI	In-line → Outperform
2021-10-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-10	Iniziato	BofA Securities	Buy
2021-02-26	Iniziato	Guggenheim	Buy
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-07-20	Reiterato	H.C. Wainwright	Buy
2020-07-07	Iniziato	Chardan Capital Markets	Buy
2020-07-01	Reiterato	H.C. Wainwright	Buy
2020-03-02	Iniziato	H.C. Wainwright	Buy
2020-02-10	Iniziato	Canaccord Genuity	Buy
2019-07-15	Iniziato	Evercore ISI	Outperform
2019-07-15	Iniziato	JP Morgan	Overweight
2019-07-15	Iniziato	Jefferies	Buy
2019-07-15	Iniziato	ROTH Capital	Buy

Mostra tutto

Akero Therapeutics Inc Borsa (AKRO) Ultime notizie

Dec 19, 2024

Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock By Investing.com - Investing.com Australia

Dec 19, 2024

Dec 18, 2024

Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock - Investing.com India

Dec 18, 2024

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock - MarketBeat

Dec 18, 2024

Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Dec 18, 2024

Akero Therapeutics chief scientific officer sells $118,172 in stock By Investing.com - Investing.com South Africa

Dec 18, 2024

Akero Therapeutics executive sells $264k in stock By Investing.com - Investing.com Canada

Dec 18, 2024

Akero Therapeutics chief scientific officer sells $118,172 in stock - Investing.com

Dec 18, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - AccessWire

Dec 18, 2024

Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.1%What's Next? - MarketBeat

Dec 18, 2024

State Street Corp Has $71.81 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Dec 18, 2024

Fmr LLC Purchases 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Dec 18, 2024

Dec 17, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Up 3.5%Here's What Happened - MarketBeat

Dec 17, 2024

Dec 15, 2024

AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc.AKRO - The Eastern Progress Online

Dec 15, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - AccessWire

Dec 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in November - MarketBeat

Dec 15, 2024

Dec 13, 2024

Akero Therapeutics' chief development officer sells $86,519 in stock By Investing.com - Investing.com South Africa

Dec 13, 2024

Akero Therapeutics chief scientific officer sells $148,933 in shares By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

Akero Therapeutics COO sells shares worth $77,067 - Investing.com India

Dec 12, 2024

Akero Therapeutics COO sells shares worth $77,067 By Investing.com - Investing.com South Africa

Dec 12, 2024

Akero Therapeutics executive sells $28,480 in common stock By Investing.com - Investing.com South Africa

Dec 12, 2024

Akero Therapeutics CFO sells $86,735 in stock By Investing.com - Investing.com Canada

Dec 12, 2024

Akero Therapeutics CFO sells $86,735 in stock - Investing.com

Dec 12, 2024

Akero Therapeutics' chief development officer sells $86,519 in stock - Investing.com

Dec 12, 2024

(AKRO) Technical Data - Stock Traders Daily

Dec 12, 2024